Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion
- 8 May 1992
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 51 (2) , 182-188
- https://doi.org/10.1002/ijc.2910510204
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)Investigational New Drugs, 1986
- Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusionInvestigational New Drugs, 1985
- Studies on the mechanism of action of 2-β-d-ribofuranosylthiazole-4-carboxamide—VBiochemical Pharmacology, 1984
- Tiazofurin: A new antitumor agentInvestigational New Drugs, 1984
- Studies on the mechanism of action of 2-β-d-ribofuranosylthiazole-4-carboxamide (NSC 286193)-IIBiochemical Pharmacology, 1982
- Inhibition of inosinate dehydrogenase by metabolites of 2-β-D-ribofuranosylthiazole-4-car☐amideBiochemical and Biophysical Research Communications, 1982
- Mechanism of resistance to the oncolytic C-nucleoside 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC-286193)Biochemical Pharmacology, 1982
- Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide NSC 286193)Biochemical Pharmacology, 1982
- The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory propertiesBiochemical Pharmacology, 1982
- Mlab — A mathematical modeling toolComputer Programs in Biomedicine, 1979